A paper copy of the Sequence Listing and a computer readable form of the Sequence Listing containing the file named “21UMC068 Sequence Listing Replacement 03.29.2023_ST25,” which is 3,651 bytes in size (as measured in MICROSOFT WINDOWS® EXPLORER) and was created on Mar. 29, 2023, are provided herein and are herein incorporated by reference. This Sequence Listing consists of SEQ ID NOs: 1-8.
The present disclosure relates to amphiphilic peptide chaperones, pharmaceutical compositions comprising these amphiphilic peptide chaperones, and their methods of use. More specifically, the present disclosure relates to their use in preventing or reducing a source of stress in cells or a patient and/or the treatment of a disorder such as paralysis, COVID-19, COVID-19 mutant, diabetes, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), cataract, age-related macular degeneration (AMD), glaucoma, or retinitis pigmentosa.
Diverse protein conformational diseases, including Alzheimer's, Parkinson's disease, amyotrophic lateral sclerosis, cataract, retinitis pigmentosa, etc., follow a common structural and pathological pathway. Therapeutic interventions to prevent, delay, or stop the accumulation of misfolded proteins and associated diseases would significantly reduce health care costs and the burden of suffering from such conditions. Medical expenses for the many protein conformational diseases drive up health care costs by tens of billions of dollars. The development of therapies for such diseases is intrinsic to reducing costs and improving the quality of life in the elderly. Under development as frontline therapies to prevent protein misfolding and the ensuing cellular dysfunction and death are various molecular chaperones, including small molecules and protein and peptide chaperones that selectively bind to and stabilize the target proteins. However, the majority of chaperones tested thus far lack in vivo specificity or act against only one of the several pathological events associated with the disease.
The disclosure provides amphiphilic peptide chaperones and their incorporation into pharmaceutical compositions and their methods of use.
In one aspect, the disclosure is directed to an amphiphilic peptide chaperone comprising an amino acid sequence having at least 80% identity to LFVIFLVHFSPGRDEDKDEK (SEQ ID NO: 1) or lfviflvhfspgrdedkdek.
Another aspect of the disclosure is a nucleic acid comprising a nucleotide sequence encoding the peptide of the amphiphilic peptide chaperone, an expression vector comprising the nucleic acid, and a host cell comprising the expression vector.
Yet another aspect of the invention is a pharmaceutical composition, wherein the composition comprises the above amphiphilic peptide chaperone.
A further aspect of the disclosure is a method of preventing or treating a disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition.
This description is merely exemplary in nature and is in no way intended to limit the present teachings, application, or uses. Throughout this specification, like reference numerals are used to refer to like elements.
Amphiphilic Peptide Chaperone
The present disclosure is directed to an amphiphilic peptide chaperone comprising an amino acid sequence having at least 80% identity to LFVIFLVHFSPGRDEDKDEK (SEQ ID NO: 1) or lfviflvhfspgrdedkdek. The amino acid sequence can have at least 90%, at least 95%, at least 99%, or at least 99.9% sequence identity to LFVIFLVHFSPGRDEDKDEK (SEQ ID NO: 1) or lfviflvhfspgrdedkdek. The amino acid sequence can comprise or consist of LFVIFLVHFSPGRDEDKDEK (SEQ ID NO: 1) or lfviflvhfspgrdedkdek. The chaperone can comprise an analog or derivative of a peptide comprising an amino acid sequence LFVIFLVHFSPGRDEDKDEK (SEQ ID NO: 1) or lfviflvhfspgrdedkdek. The amino acid sequence can comprise a variant of LFVIFLVHFSPGRDEDKDEK (SEQ ID NO: 1) or lfviflvhfspgrdedkdek with at least one insertion, deletion, or substitution.
The amino acid sequence can include only L-amino acids or the amino acid sequence includes only D-amino acids. The amino acid sequence can include only D-amino acids, and the peptide chaperone comprising the amino acid sequence including only D-amino acids can have increased stability and biological activity compared to the peptide chaperone comprising the amino acid sequence including only L-amino acids. Uppercase letters indicate L-amino acids, and lowercase letters indicate D-amino acids.
The chaperone can further comprise at least one chemical modification selected from the group consisting of myristoylation, phosphorylation, acetylation, methylation, glycosylation, ADP-ribosylation, amidation, lipid addition, oxidation, palmitoylation, FLAG tagging, and tetramethylrhodamine labeling. The chaperone can be conjugated with one or more fatty acids to improve peptide pharmacokinetics. The chaperone can be myristoylated and/or labeled with tetramethylrhodamine. The N-terminus of the amino acid sequence can be myristoylated and/or labeled with tetramethylrhodamine; preferably, the N-terminus of the amino acid sequence is labeled with tetramethylrhodamine and then myristoylated. The C-terminus of the amino acid sequence can be FLAG tagged. At least one amino acid of the amino acid sequence can be phosphorylated; preferably, the amino acid sequence comprises LFVIFLVHF{pSer}PGRDEDKDEK (SEQ ID NO: 6), wherein {pSer} indicates a phosphorylated serine amino acid. For any of the chaperones of this disclosure, the N-terminus of the amino acid sequence can have a CH3 modification and/or the C-terminus of the amino acid sequence can have a NH2 modification.
Preferably, the chaperone can have cell-penetrating and protease-resistant properties and is non-toxic to cells. The chaperone can also help maintain cellular homeostasis and increase longevity. The chaperone can protect cells and tissues from oxidative stress and apoptosis. Preferably, the chaperone assists in protein folding or refolding during or after synthesis.
The chaperone can have the ability to self-assemble with other like chaperones as spherical nanoparticles. Preferably, the nanoparticles are about 20-30 nm in diameter.
The chaperone can prevent or reduce a source of stress in cells. Preferably, the source of stress is selected from the list consisting of beta-amyloid oligomerization and deposition, induced cytotoxicity, oxidative stress, protein aggregation, inflammation, apoptosis, hyperglycemia, hemolytic activity of melittin, aging, and heat stress. Most preferably, the source of stress leads to aggregated protein.
The chaperone or peptide can be expressed using a transgenic cell line or a transgenic organism. A nucleic acid can be made comprising a nucleotide sequence encoding the peptide of any of the chaperones described in this disclosure. This nucleic acid can then be incorporated into an expression vector. The expression vector can further comprise other components, such as tags for the chaperone and promoters to promote expression of the chaperone in one or more organisms. Exemplary tags include GFP and FLAG tags. A host cell and/or organism comprising the expression vector can express the chaperone.
As used herein, “amphiphilic” indicates a compound or peptide has both hydrophilic and hydrophobic moieties.
As used herein, a “chaperone” is a protein or peptide that helps in the correct folding of peptides or proteins, prevents peptide or protein aggregation, blocks the formation of toxic aggregates, and helps in the secretion of peptides or proteins from cells.
As used herein, a “transgenic” cell line or organism refers to a cell line or organism that has had an exogenous nucleic acid sequence introduced to its genome. Introduction of the exogenous nucleic acid sequence can be performed with any transformation method commonly known in the art, which can include but is not limited to CRISPR-Cas9-mediated transformation and viral infection. The cell line can be an immortalized or primary cell line.
Pharmaceutical Composition
A pharmaceutical composition can be formulated, wherein the composition comprises one or more of the amphiphilic peptide chaperones described above. The composition can have similar properties to the amphiphilic peptide chaperones described above. The composition can help maintain cellular homeostasis in a subject. The composition can also prevent or reduce a source of stress in cells of a subject. Preferably, the source of stress is selected from the list consisting of beta-amyloid oligomerization and deposition, induced cytotoxicity, oxidative stress, protein aggregation, inflammation, apoptosis, hyperglycemia, the hemolytic activity of melittin, aging, and heat stress.
The composition can be useful for preventing or treating a disorder in a subject in need thereof. Preferably, the disorder is selected from the group consisting of paralysis, COVID-19, COVID-19 mutant, diabetes, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), cataract, retinitis pigmentosa, age-related macular degeneration (AMD), and glaucoma. The disorder can also be a protein conformational disease. Preferably, the protein conformational disease is selected from the list consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), cataract, age-related macular degeneration (AMD), glaucoma, and retinitis pigmentosa. The disorder can also be the result of bee venom toxin.
The pharmaceutical composition can also be formulated such that the chaperone comprises from about 0.001 to about 99.9%, about 0.001 to about 0.01%, about 0.01 to about 0.1%, about 0.1 to about 1%, about 1 to about 10%, about 10 to about 20%, about 20 to about 30%, about 30 to about 40%, about 50 to about 60%, about 60 to about 70%, about 80 to about 90%, or about 90 to about 99.9% of the total weight of the composition. The composition can further comprise a pharmaceutically acceptable excipient, carrier, and/or drug delivery agent. The composition can also further comprise an additional therapeutic small molecule.
Preferably, the composition can be administered parentally, intramuscularly, intravenously, intradermally, intranasally, or via targeted delivery. Preferably, the targeted delivery comprises injection.
The chaperone can also be self-assembled with other like chaperones as spherical nanoparticles. Preferably, these nanoparticles are about 20-30 nm in diameter. The nanoparticles can also be loaded with an additional therapeutic small molecule for targeted delivery. Preferably, the additional therapeutic small molecule is an anti-oxidant. When the chaperones are self-assembled with other like chaperones as spherical nanoparticles, the dosage can vary with the type of disease condition. For Alzheimer's disease, where there is a slow and progressive accumulation of misfolded proteins, multiple dosages may be required.
The peptides can also be delivered via extracellular vesicles. The extracellular vesicles can also be loaded with an additional therapeutic small molecule. Preferably, the additional therapeutic small molecule is an anti-oxidant. Preferably, a lower dosage of peptides is required when delivered via extracellular vesicles compared to the dosage of peptides required when not delivered via extracellular vesicles.
Methods of Use
Another aspect of the disclosure is a method of preventing or treating a disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of any of the pharmaceutical compositions described elsewhere in this disclosure.
Preferably, the disorder causes a symptom selected from the list consisting of beta-amyloid oligomerization and deposition, induced cytotoxicity, oxidative stress, protein aggregation, inflammation, apoptosis, hyperglycemia, the hemolytic activity of melittin, and heat stress.
Preferably, the disorder is selected from the group consisting of paralysis, COVID-19, COVID-19 mutant, diabetes, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), cataract, glaucoma, age-related macular degeneration (AMD), and retinitis pigmentosa.
Preferably, the disorder is a protein conformational disease. More preferably, the protein conformational disease is selected from the list consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), cataract, age-related macular degeneration (AMID), glaucoma, and retinitis pigmentosa.
The disorder can also be the result of bee venom toxin, and melittin can be present in the subject.
The subject can be a nematode or a mammal. The subject is preferably a human.
The method preferably results in transcriptional changes in the subject. Preferably, the method alters the transport and catabolism pathways (cellular processes), energy metabolism pathways, and amino acid metabolism pathways.
The following non-limiting examples are provided to further illustrate the present invention and further provides several examples of the amphiphilic peptide chaperones and their use.
The current disclosure is directed to using cell-penetrable amphiphilic peptide chaperones (CPAMCs), also called second-generation mini-chaperone peptides, to suppress protein aggregation and maintain cellular homeostasis in disease states. The CPAMC can be synthesized with D amino acids having protease-resistant properties (CPPRAMC). The CPAMC exhibits anti-aggregation activity in vitro against denaturing protein substrates. The CPPRAMC showed increased stability and biological activity. CPAMCs can be conjugated with fatty acids to improve peptide pharmacokinetics. The peptides self-assemble as spherical nanoparticles and can be loaded with small therapeutic molecules for targeted delivery.
In Table 1 and elsewhere in this disclosure, lowercase letters indicate peptides made using D amino acids. Uppercase letters indicate peptides made using L amino acids. Peptides are indicated as being synthesized with N-terminal CH3 and C-terminal NH2 modifications. Other potential peptides include but are not limited to any of the above peptides synthesized with N- or C-terminal FITC or TAMRA/TMR label to monitor peptide entry and fate.
Phosphorylated peptides (LFVIFLVHF{pSer}PGRDEDKDEK) (SEQ ID NO: 6) and peptides having an extended C-terminal arrangement with a FLAG tag (CH3-LFVIFLVHFSPGRDEDKDEKDYKDDDDK-NH2) (SEQ ID NO: 4) may be incorporated into the CPAMC. It has been observed that adding a FLAG tag to the C-terminal end does not alter the anti-aggregation activity of the peptide.
Properties of CPAMC are shown (
Relative chaperone activities of CPAMC, CPPRAIVIC, and Myr-CPAMC peptides were tested (
Various amphiphilic peptide chaperones were shown to suppress hemolytic activity of melittin, a major component of bee venom.
Hemolysis of human red blood cells with melittin was measured with varying concentrations of CPAMC (
The ability of CPAMC peptide to block the cytotoxic action of melittin on human primary lens epithelial (HLE-1°) cells was investigated. Cell viability imaging was performed with dead cells identified by fluorescent staining. HLE-1° cells cultured on a 96-well plate were treated with 1 μM melittin and/or different concentrations of CPAMC peptide for 45 min. At the end of the incubation, cell viability imaging was done using the EarlyTox cell integrity kit (Molecular Devices, Sunnyvale, Calif.) (
The protective effect of Myr-CPAMC peptide of human red blood cells (RBC) from melittin-induced hemolysis was also examined. To 0.3 mL of 2% human RBC suspension was added to melittin and/or peptide taken in 0.7 mL of PBS. The tubes were incubated at room temperature for 30 min, centrifuged (
Sodium iodate is a chemical that induces oxidative stress and cell death. The ability of CPPRAMC peptide to block the cytotoxic action of sodium iodate was investigated. ARPE-19 cells cultured on a 96-well plate were treated with 7.5 mM sodium iodate and/or CPPRAMC peptide for 24 hours. At the end of the incubation, cell viability imaging was done using the EarlyTox cell integrity kit (Molecular Devices, Sunnyvale, Calif.) (
The ability of CPPRAMC and CPAMC to suppress sodium iodate-induced oxidative stress in ARPE-19 cells was also assessed. ARPE-19 cells seeded on a 96-well plate were treated with 7.5 mM of sodium iodate and peptides in 100 μl of serum-free DMEM/F12 media for 24 hrs. The cells were then stained with 10 μM DCFH-DA for 30 min at 37° C. in the dark and the cells were observed under the EVOS FL Auto2 imaging system (Thermo Fisher Scientific, Waltham, Mass., USA) with 10× magnification. CPPRAMC and CPAMC were found to reduce or block the oxidative stress induced by sodium iodate as measured by DCFH-DA staining (
The ability of Myr-CPAMC peptide to block the cytotoxic action of sodium iodate was also investigated. Authenticated ARPE-19 cells cultured on a 96-well plate were treated with 7.5 mM sodium iodate and/or Myr-CPAMC peptide for 24 hours. At the end of the incubation, cell viability imaging was done using the EarlyTox cell integrity kit (Molecular Devices, Sunnyvale, Calif.) (
The ability of CPPRAMC peptide to protect against Aβ1-42-induced cytotoxicity was also investigated. Aβ1-42 and CPPRAMC peptides (1:1 and 1:2) were incubated at 37° C. for 2 hours and treated to ARPE-19 cells cultured on a 96-well plate. After 24 hours, the plate was imaged after staining with EarlyTox cell integrity kit (Molecular Devices, Sunnyvale, Calif.) (
The ability of the CPPRAMC to inhibit β-amyloid fibril formation was tested by incubating the chaperone peptide and human Aβ1-42 peptide at 37° C. in PBS (pH 7.4) containing 0.4% NaN3 for up to three days. The incubation mixtures were processed for TEM, and the images were captured (
Cell viability imaging was performed on cells with increasing concentrations of Myr-CPAMC, with fluorescent staining used to indicate dead cells (
Fluorescent staining indicating Myr(TMR)-CPAMC demonstrates that Myr-(TMR)-CPAMC peptide can enter into ARPE-19 cells at different concentrations (
A schematic of an assay of C. elegans N2 lifespan at 20° C. is shown (
The Kaplan-Meier survival analysis shows that worms treated with the amphiphilic peptide chaperones survive longer than the control (
The lifespan of wild type C. elegans with and without peptide at a restrictive temperature was measured.
A schematic representation of the thermotolerance assay used is shown (
CL2006 C. elegans were used as a paralysis and death model. Worms are maintained at 15° C., with adult onset paralysis induced at 20° C.
50 μg CPAMC and CPPRAMC peptide or controls were added to CL2006 worms, and the fraction left alive over time at the restrictive temperature of 20° C. was quantified (
CL4176 C. elegans is a temperature sensitive strain. Worms are maintained at 15° C. and shifted to increased temperature to cause Aβ-induced paralysis in adults. This has been used as a C. elegans model of Alzheimer's disease.
A scheme of a paralysis assay with CL4176 worms is shown (
A Kaplan-Meier Survival Analysis demonstrates how CPPRAMC and CPAMC increase survivability in CL4176 worms (
Example images of paralyzed and non-paralyzed worms are shown (
The ability of these peptides to protect against oxidative stress induced by Paraquat (PQ) or Juglone (JG) was investigated.
Five-day old N2 worms were pretreated with 50 μg peptide for 24 hours and subjected to 50 mM PQ. The survival of the worms was monitored every hour under a microscope until the end of survival. Worms that do not show any movement or response while poking were considered dead. The median survival value (50% survival) in CPPRAMC, CPAMC, and CP-SC (control) peptides corresponds to 9.6 h, 8.9 h and 5.9 h, respectively, as compared to vehicle control (5.5 h) (
N2 worms at day 5 pretreated for 24 h with 50 μg CPAMC or CP-SC (control) and subjected to 50 μM JG. Survival was checked every hour under a microscope until the end of survival. The median survival value in CPAMC and CP-SC (control) peptides corresponds to 7.3 h and 5.9 h, respectively, compared to vehicle control (4.9 h) (
FITC-labeled CPPRAMC peptides were loaded onto extracellular vesicles (EVs) by incubation at 37° C. The size of these EVs was quantified by dynamic light scattering analysis (
CPPRAMC is resistant to proteolytic cleavage as shown by HPLC profiles of overnight incubations of chaperone peptides (100 μg) with Proteinase K (10 μg) (
ARPE-19 cells, hiPSC-NSC cultures, and NSC-derived neurons treated with FITC-labeled CPPRAMC have a signal for the peptide, indicating that CPPRAMC readily penetrates neural cells (
Mouse macrophages were treated with CPPRAMC and/or LPS, and IL6 in the cell culture supernatants was measured 24 h after treatment using mouse IL6 DuoSet ELISA (R&D systems) (
HEK293 IL-6 reporter cells were treated with human recombinant IL-6 and the peptides for 1 hr. The STAT3-stimulated SEAP activity in the culture supernatant was measured using QUANTI-Blue solution (InvivoGen) (
The design of the peptide expression vector for expressing GFP-fused peptide in Cos7 cells is shown (
A Western blot analysis of Cos7 culture supernatants expressing secretory proteins probed with anti-GFP antibody produces a strong band (
Cos7 cells expressing non-secretory EGFP-CPAMC are also shown (
Thioflavin T staining in CPPRAMC-treated CL2006 and untreated CL2006 and wild type controls shows Aβ deposits (
Global transcriptional changes with the application of CPPRAMC peptide were investigated. Global transcriptional changes in C. elegans in response to CPPRAMC peptide exposure were measured and shown as a hierarchical clustering heatmap (
A KEGG Enrichment Scatter Plot of this data shows that the oxidative phosphorylation C. elegans pathway is associated with differentially expressed genes (
The increased worm lifespan and alleviation of Aβ-induced toxicity up on CPPRAMC treatment are likely mediated by the activation of molecules involved in stress response pathways. These findings signify the therapeutic prospective of CPPRAMC against oxidative stress, aging, and age-concerned Alzheimer's disease.
A summary of study schematics and proposed future testing is shown (
This study evaluated the therapeutic efficacy of CPPRAMCs in treating Alzheimer's disease using cell culture and C. elegans model systems. CPPRAMC affects aged and diseased cells like those found in patients with Alzheimer's disease. In normal cells, CPPRAMC provides a steady pool of ATP-independent chaperones that serve as the first line of passive defense during protein unfolding stresses. It also helps maintain proteostasis and cellular homeostasis and modulates cellular bioenergetics leading to decreased cellular senescence and increased longevity. In aged and diseased cells, CPPRAMC prevents Aβ oligomerization and senile plaque formation. It suppresses ROS buildup and exhibits anti-oxidative properties. It shows anti-apoptotic activity by blocking caspase activation. It suppresses inflammatory processes. It helps to maintain cellular homeostasis and bioenergetics and improves cellular function and survival. Extracellularly, CPPRAMC binds directly to Aβ monomers and oligomers and prevents senile plaque formation. It interacts with toxic misfolded proteins and neutralized them. It also binds to proinflammatory cytokines and exhibits an anti-inflammatory effect.
The peptide also protects ARPE-19 cells from sodium iodate-induced oxidative stress and apoptosis. The CPAMC's block mellitin-induced hemolytic and cytotoxic activities could serve as a therapeutic against bee venom toxin. The test compounds were not toxic to cells but protected ARPE-19 cells from Aβ1-42-induced cytotoxicity. C. elegans fed with CPAMC's have higher thermotolerance and live longer. CPAMC's mitigate beta-amyloid oligomerization and deposition in the transgenic C. elegans models of Alzheimer's disease and alleviates Aβ-induced paralysis. Worms maintained with high glucose concentrations, mimicking the hyperglycemic conditions, survived longer when fed with CPAMCs. C. elegans exposed to reactive oxygen species generating compounds like paraquat and juglone survive longer when treated with the amphiphilic peptide. This study shows that CPAMCs can be used to treat protein aggregation diseases and associated pathology.
In conclusion, amphiphilic peptides can suppress the aggregation and accumulation of misfolded proteins and help maintain cellular homeostasis. The amphiphilic peptide protects cells from oxidative stress and prevents apoptosis. CPAMCs prevent Aβ-induced toxicity on cells, and blocks melittin-induced red blood cell hemolysis. The peptide also alleviates Aβ-induced paralysis in a C. elegans model for Alzheimer's disease and increases the worm's lifespan. The amphiphilic peptide improves the life-span of C. elegans maintained with high glucose concentrations to mimic hyperglycemic conditions. These properties display a broad therapeutic potential for amphiphilic peptide chaperones, particularly for paralysis and Alzheimer's disease.
While the invention has been described in connection with specific embodiments thereof, it will be understood that the inventive methodology is capable of further modifications. This patent application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features herein before set forth and as follows in scope of the appended claims.
When introducing elements of the present invention or the embodiments(s) thereof, the articles “a”, “an”, “the” and “said” are intended to mean that there are one or more of the elements. The terms “comprising”, “including” and “having” are intended to be inclusive and mean that there may be additional elements other than the listed elements.
In view of the above, it will be seen that the several objects of the invention are achieved and other advantageous results attained.
As various changes could be made in the above compositions and methods without departing from the scope of the invention, it is intended that all matter contained in the above description shall be interpreted as illustrative and not in a limiting sense.
This application claims the benefit of U.S. Provisional Patent Application No. 63/195,876, filed Jun. 2, 2021, the entire disclosure of which is incorporated herein by reference.
This invention was made with government support under Contract Nos. R21EY029393 and R01EY023219 awarded by the National Institutes of Health (NIH) (NEI). The government has certain rights in the invention.
Number | Date | Country |
---|---|---|
2013184209 | Dec 2013 | WO |
Entry |
---|
Baranyi, L. et al. (1995). The antisense homology box: a new motif within proteins that encodes biologically active peptides. Nature medicine, 1(9), 894-901. |
Raju, M. et al. (2018). Cell-Penetrating Chaperone Peptide Prevents Protein Aggregation and Protects against Cell Apoptosis. Advanced Biosystems, 2(1), 1700095, 21 pages. |
Santhoshkumar, P. et al. (2020). A cell-penetrable mini-chaperone extends the lifespan of Caenorhabditis elegans and alleviates β amyloid-induced toxicity. Investigative Ophthalmology & Visual Science, 61(7), 2 pages. (Conference Abstract). |
Sharma, K. K. et al. (2019). Minichaperones inhibit the hemolytic activity of Mellitin. Investigative Ophthalmology & Visual Science, 60(9), 2 pages. |
Sreekumar, P. G. et al. (2013). Antiapoptotic properties of α-crystallin-derived peptide chaperones and characterization of their uptake transporters in human RPE cells. Investigative ophthalmology & visual science, 54(4), 2787-2798. |
Number | Date | Country | |
---|---|---|---|
20220387548 A1 | Dec 2022 | US |
Number | Date | Country | |
---|---|---|---|
63195876 | Jun 2021 | US |